Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
72.66
-0.16 (-0.22%)
At close: Nov 26, 2025, 4:00 PM EST
73.99
+1.33 (1.83%)
After-hours: Nov 26, 2025, 7:12 PM EST
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $354.26M in the quarter ending September 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $1.24B, up 31.19% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+31.19%
P/S Ratio
7.13
Revenue / Employee
$3,551,006
Employees
350
Market Cap
8.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HALO News
- 1 day ago - Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PRNewsWire
- 8 days ago - Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery - PRNewsWire
- 9 days ago - Why I Keep Buying These 10 Incredible Growth Stocks - The Motley Fool
- 9 days ago - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PRNewsWire
- 19 days ago - FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma - PRNewsWire
- 20 days ago - Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 - PRNewsWire
- 21 days ago - Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look - The Motley Fool
- 21 days ago - Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 - PRNewsWire